1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > PD-1 and PD-L1 Inhibitors - Competitive Landscape, Pipeline and Market Analysis, 2016

DelveInsight Report, “PD-1 and PD-L1 inhibitors - Competitive Landscape, Pipeline and Market Analysis, 2016” gives the comprehensive insights on the PD-1 and PDl-1 Inhibitors. The report has provided the analysis on the worldwide therapeutic market of PD-1 and PD-L1 inhibitors including information of Marketed molecules, detailed profiling of Pipeline assets and their pathways. The report has covered the therapeutics assessment of pipeline molecules by mechanism of action (MoA), route of administration (RoA), molecule type, along with latest updates. Report is also dealing with detailed epidemiology of all prevalent indications.

Report has also covered other Commercial Aspects such as the Current and Future Market, Barriers and challenges, SWOT analysis. Report has described the unmet needs covered by PD-1 and PD-L1 inhibitors and highlighted the side effects and toxic effects related to PD-1 and PD-L1 inhibitors which are major concerns in the market for the usage of PD-1 and PD-L1 inhibitors.

The report has also thrown light on the combinations therapies with Immune-check point Inhibitors (PD-1 and PDL-1), provided the information of ongoing collaborations for the development of combinations regimens.
DelveInsight Analysis predicts that PD-1 and PD-L1 inhibitors are among the highly growing fields in biopharmaceutical industry. Most of these immunotherapeutic are being used in Oncology. There are 51 drugs are in pipeline with approximate 245 active clinical studies. Companies have also gone in collaboration with different partners like Bristol, Merck, Astrazeneca and Roche for evaluating their drugs in combination with Immune Checkpoint Inhibitors (PD-1/PD-L1). There are total 37 companies found which have partnered with various Big Pharmas.
Out of 51 drugs, 44 drugs are in Monotherapy and 7 drugs are in the combination therapy. Out of 43 Monotherapy drugs, 2 is in Filed stage and 3 drugs are in phase III, 2 drug is in Phase II, 9 drugs are in Phase I, 19 drugs are in Pre-Clinical and 7 drugs are in discovery phase and 2 in Unknown stage. Out of 7 combination therapy drugs 2 are in Phase I, 2 are in Pre-Clinical stage of development and 3 are in Discovery stage.

Future competitive landscape of PD-1 and PD-L1 inhibitors is estimated to be very strong. There are 3 marketed products of PD-1 and PD-L1 inhibitors. Treatment options such as surgery, chemotherapy, radiation therapy, and many others are able to fulfill the current unmet need to an extent. The market for PD-1 and PD-L1 drugs might be billions of dollars in coming years. These drugs which include Bristol-Myers' Opdivo, Merck's Keytruda and Hoffmann-La Roche' Tecentriq are going to be the blockbuster molecules in upcoming years.
PD-1 and PD-L-1 inhibitors are showing greater efficacy as immune-therapeutic drugs but with the immune system unchecked, there is the possibility that immune cells attack other parts of the body, causing serious problems in the intestines, liver, nerves, eyes, or other organs. Although Preliminary data suggests that PD-1/PD-L1 immunotherapies provide faster and more frequent responses.

Table Of Contents

PD-1 and PD-L1 Inhibitors - Competitive Landscape, Pipeline and Market Analysis, 2016

Illustrative Table of contents


- Introduction
- Executive Summary
- Programmed Death 1 (PD-1)
- Programmed Death Ligand 1 (PD-L1)
- Role of PD-1 and PD-L1 pathways
- MOA of PD-1 and PD-L1 inhibitors
- Significance of PD-1 and PD-L1 inhibitors
- PD-1 and PD-L1 Active Therapy Areas and Epidemiology
- Squamous Cell Carcinomas of the Head and Neck
- Metastatic Colorectal Cancer
- Non-Small Cell lung cancer
- Biomarkers - PD-1 and PD-L1 inhibitors
- Market Overview
- Comparative Analysis of Pipeline andMarketed Drugs
- Marketed Product of PD-1 and PD-L1 drugs -Overview
- Marketed Drug Candidate Profiles
- Pembrolizumab
- Nivolumab
- Atezolizumab
- Marketed Drugs Sales
- Details of Patent Expiry of Marketed Drugs
- Current and Future Market for PD and PD-L1 inhibitors
- Challenges and Barriers associated with use of PD and PD-L1 inhibitors
- PD-1/PD-L1Combinations Creating Boom
- Pipeline Therapeutics
- An overview of pipeline products
- Therapeutics under Development by MOA
- Therapeutics under Development by Companies
- Phase III and Filed Molecules
- Product Description
- Research and Development
- Product Development Activities
- Phase II Molecules
- PDR001: Novartis
- Product Description
- Research and Development
- Product Development Activities
- Phase I Molecules
-
- Research and Development
- Product Development Activities
- Pre-clinical Stage Molecules
- Product Description
- Research and Development
- Product Development Activities
- Discovery Stage Molecules
- Product Description
- Research and Development
- Product Development Activities
- Therapeutic Assessment of pipeline
- Therapeutics under Development by Product Type
- Therapeutics under Development by Phase for Monotherapy
- Therapeutics under Development by Phase for Combination therapy
- Therapeutics under Development by Molecule Type
- Therapeutics under Development by Route of Administration
- SWOT Analysis
- Appendix
- Methodology
- Consulting Services
- About DelveInsight
- Contact Us
- Disclaimer
List of Tables


Table 1: Marketed and Pipeline drugs forPD-1 and PD-L1 Drugs, 2016
Table 2: PD-1 Marketed Drugs, 2016
Table 3: Sales of Marketed drugs, 2016
Table 4: Details of patent expiry of marketed molecules, 2016
Table 5: Bristol Myers Squibb's drug-Opdivo Partners for Combination Therapies
Table 6: Merck's drug- Keytruda (Pembrolizumab) Partners for Combination Therapies
Table 7:AstraZeneca's drug- Durvalumab (MEDI4736) Partners for Combination Therapies
Table 8: Roche's drug-Atezolizumab (MPDL-3280A) Partners for Combination Therapies
Table 9: Number of Products Under Development for PD-1 and PD-L1 inhibitors Drugs, 2016
Table 10: ComparativeTable forPD-1 and PD-L1 inhibitors Drugs, 2016
Table 11: Number of Products under Development by Companies, 2016
Table 12: Number of Products by Product Type for PD-1 and PD-L1 Inhibitors, 2016
Table 13: Number of Monotherapy Products for PD-1 and PD-L1 inhibitors, 2016
Table 14: Number of Combination therapy Products forPD-1 and PD-L1 inhibitors, 2016
Table 15: Number of Products under Development by Molecule Type, 2016
Table 16:Number of Products under Development by Route of Administration, 2016
List of Figures


Figure 1:Marketed and Pipeline drugs forPD-1 and PD-L1 Drugs, 2016
Figure 2: Sales of marketed drugs, 2016
Figure 3: Details of patent expiry of marketed molecules, 2016
Figure 4: Number of Products under Development for PD-1 and PD-L1 inhibitors Drugs, 2016
Figure 5: Comparative Graph for PD-1 and PD-L1 inhibitors Drugs, 2016
Figure 6: Number of Products by Product Type forPD-1 and PD-L1 Inhibitors, 2016
Figure 7: Number of Monotherapy Products forPD-1 and PD-L1 inhibitors, 2016
Figure 8: Number of Combination therapy Products forPD-1 and PD-L1 inhibitors, 2016
Figure 9: Percentage of pipeline drugs by Molecule Type (%), 2016
Figure 10: Percentage of pipeline drugs by Route of Administration(%), 2016

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • August 2016
  • by Global Data

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025 Summary Cardiovascular diseases (CVD), including ischemic heart disease and stroke, are the leading causes of mortality ...

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Ulcerative Colitis: KOL Insight

Ulcerative Colitis: KOL Insight

  • $ 8085
  • Industry report
  • September 2016
  • by Firstword Pharma

Are UC biosimilars a real or perceived threat to branded drugs? Ulcerative colitis (UC) treatment is on the brink. Patents are ending on various branded drugs and clearing the way for an influx of biosimilars; ...

Hepatitis C: Kol Insight

September 2016 $ 8085

Download Unlimited Documents from Trusted Public Sources

Therapy and Hormone Market in South Korea

  • December 2016
    4 pages
  • Therapy  

    Hormone  

    Cancer  

  • South Korea  

View report >

Opioid Market in the US

  • December 2016
    14 pages
  • Opioid  

  • United States  

View report >

Therapy Market in Denmark - Forecast

  • December 2016
    12 pages
  • Therapy  

  • Denmark  

View report >

Related Market Segments :

Therapy

ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.